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ABSTRACT
Objective To determine whether ultraviolet B
phototherapy at home is equally safe and equally
effective as ultraviolet B phototherapy in an outpatient
setting for patients with psoriasis.
Design Pragmatic multicentre single blind randomised
clinical trial (PLUTO study).
Setting Dermatology departments of 14 hospitals in the
Netherlands.
Participants 196 patients with psoriasis who were
clinically eligible for narrowband (TL-01) ultraviolet B
phototherapy. The first 105 consecutive patients were
also followed for one year after therapy.
Intervention Ultraviolet B phototherapy at home using a
TL-01 home phototherapy unit compared with standard
narrowband ultraviolet B phototherapy in an outpatient
setting. Both therapies were done in a setting reflecting
routine daily practice in the Netherlands.
MainoutcomemeasuresThemainoutcomemeasurewas
effectiveness as measured by the proportion of patients
with a 50% or more reduction of the baseline psoriasis
area and severity index (PASI) or self administered
psoriasis area and severity index (SAPASI), called the
PASI 50 and SAPASI 50 (relevant treatment effect).
Another outcome of effectiveness was the percentage
reductioninmedianscoresonthePASIaswellasSAPASI.
Also the proportions of patientsreaching the PASI 75 and
SAPASI 75 (successful treatment effect), and the PASI 90
and SAPASI 90 (almost complete clearance) were
calculated.Othersecondaryoutcomeswerequalityoflife
(SF-36, psoriasis disability index), burden of treatment
(questionnaire), patients’ preferences and satisfaction
(questionnaire), and dosimetry and short term side
effects (diary).
Results 82% of the patients treated at home compared
with 79% of the patients treated in an outpatient setting
reachedtheSAPASI50(difference2.8%,95%confidence
interval −8.6% to 14.2%), and 70% compared with 73%
reached the PASI 50 (−2.3%, −15.7% to 11.1%). For
patients treated at home the median SAPASI score
decreased 82% (from 6.7 to 1.2) and the median PASI
score decreased 74% (from 8.4 to 2.2), compared with
79% (from 7.0 to 1.4) and 70% (from 7.0 to 2.1) for
patientstreatedin an outpatientsetting.Treatment effect
asdefinedbythemeandeclineinPASIandSAPASIscores
was significant (P<0.001) and similar across groups
(P>0.3). Total cumulative doses of ultraviolet B light were
similar(51.5v46.1J/cm
2,difference5.4,95%confidence
interval −5.2 to 16.0), and the occurrence of short term
side effects did not differ. The burden of undergoing
ultraviolet B phototherapy was significantly lower for
patients treated at home (differences 1.23 to 3.01, all
P≤0.001). Quality of life increased equally regardless of
treatment, but patients treated at home more often rated
their experience with the therapy as “excellent” (42%,
38/90) compared with patients treated in the outpatient
department (23%, 20/88; P=0.001).
Conclusion Ultraviolet B phototherapy administered at
home is equally safe and equally effective, both clinically
and for quality of life, as ultraviolet B phototherapy
administered in an outpatient setting. Furthermore,
ultraviolet B phototherapy at home resulted in a lower
burden of treatment and led to greater patients’
satisfaction.
Trial registration Current Controlled Trials
ISRCTN83025173 and Clinicaltrials.gov NCT00150930.
INTRODUCTION
Psoriasisisachronicskindisorderwhich,regardlessof
extent, can affect patients’ quality of life. The disease
can be treated symptomatically in several ways. An
effectivetreatmentthatisoftenappliedisphototherapy
using ultraviolet B light.
1-4 Ultraviolet B phototherapy
is indicated when topical treatment is insufficient. It is
generally offered in an outpatient clinic, which
requires patients to travel two or three times a week
for treatment. This makes it a relatively time consum-
ing treatment both for patients and for hospital staff,
imposing a substantial burden on patients and society.
To overcome the drawbacks of ultraviolet B photo-
therapy in the outpatient clinic, equipment for use at
home was introduced in the late 1970s.
5-8 Although
ultravioletBphototherapyhasbeenusedathomeever
since,
7-14 its safety and effectiveness and compliance
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based fears are often expressedabout higher attendant
risks such as inaccurate dosimetry, phototoxicity, sub-
optimal treatment, and unsupervised continuation of
irradiations after treatment has finished.
11-24 It is
thought that these risks influence the occurrence of
acute side effects and lead to an increased cumulative
dose and hence promote photocarcinogenesis and
photoageing.
We have shown that over 55% of dermatologists
consider ultraviolet B phototherapy at home to be
inferior to such therapy in the outpatient department.
Moreover, about 30% think that ultraviolet B photo-
therapy at home carries higher risks than when used
in hospital, risks such as erythema, burns, carcinogen-
esis, and photoageing.
25 Research using randomised
designs is non-existent, and literature on the subject
remains scarce—that is, firm evidence supporting or
discouraging the use of ultraviolet B phototherapy at
home is simply lacking.
25
Although many dermatologists hardly ever pre-
scribeultravioletBphototherapyathome,insomeset-
tings such treatment is common. We reported that
3000 panels for dispensing ultraviolet B light had
been sold in Germany and 5000 in the United States
and that two Dutch home care institutions (indepen-
dent suppliers of medical equipment, inclusive of sup-
port from specialist nurses) were successfully
providing ultraviolet B light equipment and supervi-
sion for 1400 patients with psoriasis annually. We
also showed that in the Netherlands about 5% of
patients treated with ultraviolet B light are prescribed
phototherapy at home. Some dermatologists even
reported prescribing home therapy to all their patients
treated with ultaviolet B light.
25
Tosummarise,firmevidenceonwhichtobaseacon-
sidered policy decision about ultraviolet B photother-
apy at home is lacking.
25 In the absence of sound
evidence based on randomised research, discussions
on home ultraviolet B phototherapy will continue to
result in the spread of non-evidence based opinions
andopinionbasedmedicine.
25Notably,little attention
has been paid to the possible positive effects of home
therapyonqualityoflife,patients’satisfaction,andthe
burden of treatment.
On the basis of recent experience with ultraviolet B
phototherapy at home and data from a 1993 pilot we
expected home treatment to be as equally effective as
current ultraviolet B phototherapy used in outpatient
settings.
9 We aimed to establish that treatment effect,
safety, quality of life, and cost effectiveness of home
phototherapy do not differ substantially from that of
conventional ultraviolet B phototherapy in an out-
patient clinic. Additionally, with home treatment we
expected a lower burden from treatment and higher
patients’ satisfaction. We compared both treatments
in a setting reflecting routine daily practice in the
Netherlands and focused on narrowband (TL-01)
ultraviolet B phototherapy for psoriasis.
26 The Dutch
acronym for this trial was PLUTO. The cost effective-
ness data will be published separately.
METHODS
From 2002 to 2005 we carried out a pragmatic multi-
centre single blinded randomised trial comparing
ultraviolet B phototherapy at home with ultraviolet B
phototherapy in an outpatient setting.
26 The partici-
pants and methods are described in detail elsewhere
(www.biomedcentral.com/content/pdf/1471-2288-6-
39.pdf).
26
Apragmatic designisa recognisedmethodologyfor
tackling questions on effectiveness in daily practice as
opposed to efficacy in a “controlled” setting.
27-29 Thus
inourtrialtheinterventionswereadministeredasthey
would be routinely, with the management of the inter-
ventionlefttothediscretionoftheprescribingclinician
—that is, dermatologists were encouraged to carry out
the assigned treatment as they would normally. Con-
sequently,partofthecomparisonispossiblevariability
in actual frequency of irradiations, dosage, compli-
ance,support,andequipmentused.Wedidnotcontrol
fortheseandotherpossibledifferencesrelatedtotreat-
ment because they will occur in a real life situation.
Besides the treatment, the selection of patients also
reflected routine practice. Blinding participants to
treatment was not possible, and because of the prag-
matic design of the study it was undesirable to blind
thedermatologists.Theextentandseverityofthepsor-
iasis was, however, assessed by an independent
research nurse blinded to the treatment arm.
26
Since patient selection should reflect routine clinical
practice,
28-30 we invited patients with plaque or guttate
psoriasis to participate if they were considered clini-
cally eligible for TL-01 ultraviolet B phototherapy.
As a result the severity of psoriasis was not a selection
criterion. Ultraviolet B treatment had to be prescribed
by the patient’s own dermatologist, and patients pro-
vided written informed consent to undergo treatment
according to randomisation. We excluded patients
younger than 18 years, those who might not comply
with treatment, those with contraindications, and for
practical reasons. Further details are described
elsewhere.
26Themainselectioncriterionofbeingclini-
callyeligible forTL-01 ultravioletBphototherapywas
purely pragmatic and was left to the discretion of the
patients’ own dermatologists. The dermatologists
were,however,explicitly discouragedfrom increasing
their prescriptions because of the study.
Sample size
On the basis of recent experience with home ultra-
violet B phototherapy and data from a 1993 pilot we
expected the treatments to be equally effective.
9 The
sample size was therefore calculated in accordance
with a negative trial approach.
31 We considered a
50% or more improvement in the severity of psoriasis
from baseline to be a relevant clinical response. From
the literature we expected about 85% of the patients
treated with ultraviolet B light to show at least a 50%
improvement of their psoriasis.
32 We determined that
with an α of 0.05, β of 0.20 (power 80%), and a distin-
guishabledecline(Δ)inproportionofpatientsof−15%
(from 85% to 70%) we would need 90 patients per
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26Toallowformissingdataandlosses
to follow-up we aimed to recruit 100 patients per
group, 200 in total. From the end of the treatment
onwards we considered a consecutive sample of 100
patients (50 per group) to be sufficient to obtain accu-
rate estimates of cumulative costs.
26
Randomisation procedure
After baseline data had been collected, a randomisa-
tionnumbercorrespondingtoultravioletBphotother-
apy either at home or in an outpatient department was
drawn froma computer generatedlist.Randomisation
was done using stratified randomisation, in particular
the minimisation method.
2633 This method takes into
account the recruiting hospital and possible previous
experiences with ultraviolet phototherapy. After ran-
domisation both the patient and the dermatologist
wereinformedoftheassignedtreatment,andthistreat-
ment was started according to standard practice.
Therapy
Patients randomised to outpatient treatment received
TL-01 ultraviolet B phototherapy in their local hospi-
tal. The hospitals used their own treatment schedules
andtheirown(fullcircle)units.Sometypesofunitshad
ultraviolet light indicators measuring the intensity of
irradiation (mW/cm
2); others did not and measured
only treatment time. Accordingly, treatments were
prescribed either in dose (J/cm
2) or in units of time
(seconds).
26 Determination of the minimal erythema
dosebeforetreatmentwasonlydoneifthatwasroutine
practice for the hospital. Patients were treated two or
three times a week, depending on the hospital.
Patients randomised to receive home ultraviolet B
phototherapy were temporarily provided with a TL-
01 home phototherapy unit (Waldmann UV 100;
Waldmann, Villingen-Schwenningen, Germany).
This device comprises a semicircular arrangement of
lamps without an intensity indicator. Therefore treat-
ments were prescribed in units of time (seconds). The
equipment was rented out by the home care institu-
tions, which also delivered the unit to the patients’
home and collected it at the end of the treatment per-
iod. On delivery, a nurse from the home care institu-
tionprovided30-60minutes’traininginuseoftheunit.
Patients signed a contract restricting use of the unit to
themselves. Finally, the patients received a treatment
schedule, set in time (seconds). No minimal erythema
dose was tested. Irradiation took place three or four
times a week (every other day), sometimes starting
with daily irradiations. The choice of subsequent
stepsinthetreatmentscheduledependedontheextent
ofsideeffectsexperienced(erythemaorburningsensa-
tion). Patients could contact the nursing staff of the
home care institution for supervision. The cost for the
nurses’services,delivery,andcollectionoftheunitwas
included in the rental price.
26
Summarising, the irradiation schedules for both
treatmentgroupswerethosenormallyusedbythehos-
pitals and home care institutions. Neither equipment
norschedulesweremodifiedforthetrial.Weobserved
standard practice and therefore did not impose a pre-
specifiedtreatmentregimenontheparticipants,andas
with daily practice we allowed adjuvant use of topical
therapy to continue throughout ultraviolet B treat-
ment. No other additional treatments or changes to
the original treatment plan were intended. However,
to compare the two treatments under practical condi-
tions and to reflect clinical reality, alterations to the
initial treatment plan were allowed if the dermatolo-
gistsdecidedtheywerenecessary.Assuch,allchanges
totreatmentoriginatingafterinclusionandrandomisa-
tion were permitted and were no reason for
exclusion.
26
Outcome measures
We determined the severity of disease by using the
psoriasis area and severity index (PASI)
34 and the self
administered psoriasis area and severity index
(SAPASI).
35-37 Both scales range from 0 (no lesions) to
72 (extensive erythroderma of the severest degree).
The main outcome measure was effectiveness, as mea-
suredbytheproportionofpatientswitha50%ormore
improvement of the baseline PASI or SAPASI (called,
respectively, PASI 50 and SAPASI 50), which is con-
sidered a relevant treatment effect. Another outcome
measurewasthepercentagereductioninmedianPASI
andSAPASIscores.Also,thePASI75andSAPASI75
(proportion of patients reaching a 75% improvement
of the PASI and SAPASI, a so called successful treat-
menteffect),thePASI90andSAPASI90(almostcom-
plete clearance), and a patient assessed visual severity
assessment scale ranging from 0 (no psoriasis) to 100
(most severe psoriasis imaginable) were measured.
To verify whether the treatments were equally safe,
weassessedtheincidenceofacutesideeffectsandmea-
sured the total cumulative dose of ultraviolet B light.
The patients recorded any short term side effects for
every irradiation in a diary. We considered four short
term side effects of interest: mild erythema and burn-
ing sensation (mild and expected side effects) and
severe erythema and blistering (serious side effects).
To calculate cumulative doses of ultraviolet B light
we routinely measured light intensity (J/cm
2) of all
equipment from the hospitals with a small portable
ultraviolet light meter (585 100; Waldmann, Ger-
many). If the ultraviolet B unit from the hospital had
an irradiation intensity indicator, we compared its
reading with our own measurements. The home care
institutions measured the light intensity of every unit
beforethe firstirradiationand afterthelast irradiation,
using their own ultraviolet light meters (all type 585
100; Waldmann). At the end of the trial we collected
these measurements and also compared their portable
ultraviolet B light meters with our own portable ultra-
violet B light meter, which was calibrated using a high
accuracy ultraviolet visible spectroradiometer (OL
752; Optronic Laboratories, Orlando, FL). Partici-
pants in both groups recorded treatment times in
theirdiary.Wealsotookcopiesofthetreatmentcharts
of the patients treated in hospital. At the end of the
trial we calculated standardised cumulative doses
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 11(mW/cm
2) for all patients using the intensity measure-
ments together with the individual treatment charts or
diaries,orboth.Thecalculationofstandardisedcumu-
lative doses is described elsewhere.
26
To measure the perceived burden of treatment we
designed a short four item questionnaire using visual
analoguescalesrangingfrom0-10(seewebextra).The
questionnaire was drawn up to capture the perceived
burden of the ultraviolet B treatment, especially the
burden of the treatment method and time lost as a
result of treatment.
Weassessedhealthrelatedqualityoflifeusingagen-
eric and a disease specific questionnaire
26: the short
form36generalhealthsurvey(SF-36)
3839andthepsor-
iasis disability index.
4041 The SF-36 questionnaire pro-
vides eight domain scores ranging from 0 (lowest
imaginable quality of life) to 100 (perfect health).
3839
The psoriasis disability index has scores ranging from
15 (no disability, highest quality of life) to 105 (lowest
quality of life).
4041 Furthermore, we developed and
used a questionnaire on patients’ satisfaction and pre-
ferences, and collected data on concomitant use of
drugs and personal information.
26 Details on the out-
come measures are published elsewhere.
26
Planning of measurements
We planned measurements for the 196 participants
coinciding with inclusion in the study (t=0), actual
start of therapy (t=1), around the 23rd irradiation
(t=2), and the end of therapy (t=3). When treatments
exceeded 46 irradiations, we defined 46 irradiations
as the end of therapy.
26
To obtain accurate estimates of cumulative costs,
some measurements continued every two months for
one year after the end of therapy (measurements 4 to
9). For this objective only 100 participants were
needed;thereforethefirstconsecutive105participants
were followed for these measurements. Figure 1 sche-
matically represents the planned measurements.
Statistical analysis
The main principle of our analysis was non-inferiority
—that is, we hypothesised that there would be no dif-
ferences between treatments in clinical outcome, qual-
ityoflife,andsafety.Thenon-inferioritymargin(Δ)for
the primary outcome measures PASI 50 and SAPASI
50wassetat−15%.Non-inferiorityofhomeultraviolet
Bphototherapywasacceptedif thelowerboundofthe
two sided 95% confidence interval around the esti-
mated difference in proportion of patients reaching
PASI 50 or SAPASI50 was above −15%. We also ana-
lysed the secondary outcome measures for non-infer-
iority,usingevaluationofthelowerboundsofthe95%
confidence intervals for clinical relevance. The differ-
ences at group level are presented with their 95% con-
fidence intervals.
We used statistical methods in accordance with the
typeofdatatoanalysethesuperiorityofpatients’satis-
faction and burden of treatment. From independent
sampleswecarriedoutthe unpairedttestfornormally
distributed continuous data. For ordinal data and data
withaskeweddistributionweusedtheMann-Whitney
U test. All analyses were done according to the inten-
tion to treat principle.
RESULTS
Overall, 196 patients were randomised: 98 to home
ultraviolet B phototherapy and 98 to outpatient ultra-
violet B phototherapy (fig 2). All participants were fol-
lowedduringtherapy.Thefirst105consecutivepatients
were also followed for one year after therapy.
26
Table1summarisesthebaselinecharacteristicsofthe
196 patients. The severity of psoriasis at baseline
between those patients who completed the study and
those who dropped out did not differ. Baseline severity
ofpsoriasis ranged frommild tosevere, withindividual
PASI scores up to 48.6. One hundred patients had had
experienceofultravioletlighttreatment,eightofwhom
had experienced home phototherapy. Three of these
were allocated to home ultraviolet B phototherapy
and five to outpatient ultraviolet B phototherapy.
Treatment effect
Table2showseffectivenessasmeasuredbytheSAPASI
50,75,and90andthePASI50,75,and90.Fourofthese
sixoutcomemeasuresindicatedthathomeultravioletB
phototherapy was not inferior—that is, was equally
effective as (SAPASI 50 and PASI 90), at least equally
effective as (SAPASI 75), or even superior to (SAPASI
Therapy (n=196) Follow-up (n=105)
PASI, quality of life, medication
SAPASI
Burden of treatment
Dosimetry, treatment times, side effects
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Fig 1 | Schematic representation of planned measurements. PASI=psoriasis area and severity
index; SAPASI=self administered psoriasis area and severity index
Table 1 |Baseline characteristics of patients with psoriasis allocated to ultraviolet B
phototherapy at home or in an outpatient department. Values are means (standard errors of
means) unless stated otherwise
Characteristics Home phototherapy (n=98) Outpatient phototherapy (n=98)
No (%) of men 66 (67) 66 (67)
Age (years) 41.2 (1.38) 45.0 (1.37)
Duration of psoriasis (years) 16.1 (1.37) 16.0 (1.36)
SAPASI* 7.2 (0.38) 7.3 (0.32)
PASI† 9.7 (0.71) 8.6 (0.56)
No (%) with experience of
phototherapy
50 (51) 50 (51)
SAPASI=self administered psoriasis area and severity index; PASI=psoriasis area and severity index.
*Score had normal distribution at baseline but showed skewed distribution over course of trial.
†Score had skewed distribution during all measurements. Median values at baseline were 8.4 (home) and 7.1
(outpatient).
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The remaining two measures (PASI 50 and PASI 75)
had point estimates suggesting equal effectiveness, but
non-inferioritycouldnotbeconfirmedbythe95%con-
fidence intervals, of which the lower bounds were
slightly lower than −15%. Supplemental analyses for
both measures, however, showed that less than 5% of
the distribution of the 95% confidence intervals fell
below the margin of −15%.
The treatment effect as defined by the mean decline
inSAPASIandPASIscoreswasstatisticallysignificant
within (all P<0.001) and similar (P>0.3) across both
treatment groups.
Figure 3 illustrates changes in median psoriasis
severity(SAPASI)overtime.Duringtherapythemed-
ian SAPASI score decreased from 6.7 to 1.2 for the
home ultraviolet B group and from 7.0 to 1.4 for the
outpatient ultraviolet B group; a decline of 82% and
79%, respectively. Essentially similar results were
observed for decline in median PASI scores, from 8.4
to 2.2 for the home ultraviolet B group compared with
7.0 to 2.1 for the outpatient ultraviolet B group: a
decline of 74% and 70%, respectively. Subgroup ana-
lyses for patients with more moderate to severe psor-
iasis(baselineSAPASI≥10)showedthatthissubgroup
reacted similarly to home ultraviolet B phototherapy
as did the average participant. No differences were
observed across the treatment groups.
PASI scores measured during the three visits to the
researchnursewerecomparabletothe SAPASIscores
(data not presented). Correlation coefficients for PASI
and SAPASI scores varied between 0.48 and 0.52
(P<0.001). Mean self assessed scores for psoriasis
severity using a visual severity assessment scale
(range 0-100) were 70.6 and 70.2 at inclusion and
18.1 and 18.0 at the end of therapy (90 patients in
home ultraviolet B group v 88 in outpatient ultraviolet
B group).
Safety
To determine whether both treatments were equally
safe, the incidence of acute side effects were assessed
andthetotalcumulativedoseofultravioletBlightmea-
sured (table 2). Patients treated at home had a higher
meantotalnumberofirradiationsthanpatientstreated
in the outpatient setting. Yet the point estimate of the
mean cumulative dose of TL-01 ultraviolet B light at
the end of therapy was only slightly higher for patients
treated at home (difference 5.4 J/cm
2, 95% confidence
interval −5.2 to 16.0).
A total of 6180 irradiations were monitored. Com-
pleteinformationonsideeffectswasavailablefor6111
irradiations in 185 patients. Regardless of treatment
group, 87% (n=161) of the patients had at least one
occurrence of mild erythema, 58% (n=107) a burning
sensation,39%(n=73)severeerythema,and6%(n=11)
blistering. No differences were observed between the
treatment groups.
Besides the probability of patients experiencing a
particular side effect during the entire treatment, also
the probability per irradiation was calculated for each
patient by dividing the number of side effects during
treatment by the number of irradiations. No differ-
ences between treatment groups were observed in
these outcomes (table 2).
Adjuvant treatment, waiting time, and duration of therapy
Adjuvant treatment was divided into topical drugs (for
example, vitamin D derivatives, topical corticoster-
oids, dithranol)and systemic drugs (methotrexate, aci-
tretin, ciclosporin, fumarates). During ultraviolet B
treatment, a higher proportion of the patients treated
at in the outpatient department used topical steroids
and vitamin D derivatives, whereas during waiting
Table 2 |Main outcome measures for patients with psoriasis randomised to ultraviolet B
phototherapy at home or in an outpatient department. Values are percentages (numbers) of
patients unless stated otherwise
Variables
Home
phototherapy
Outpatient
phototherapy
Difference
(95% CI)
Effectiveness
SAPASI 50, 75, and 90*: (n=94) (n=91) —
SAPASI 50 81.9 (77) 79.1 (72) 2.8 (−8.6 to 14.2)
SAPASI 75 69.1 (65) 59.3 (54) 9.8 (−4.0 to 23.6)
SAPASI 90 43.6 (41) 29.7 (27) 13.9 (0.002 to 27.8)
PASI 50, 75, and 90†:( n =91) (n=84) —
PASI 50 70.3 (64) 72.6 (61) −2.3 (−15.7 to 11.1)
PASI 75 40.7 (37) 41.7 (35) −1.0 (−15.6 to 13.6)
PASI 90 19.8 (18) 19.0 (16) 0.8 (−10.9 to 12.5)
Safety
Irradiations: (n=98) (n=98) —
Mean No of irradiations 34.4 28.6 5.8 (2.7 to 9.0)
Mean cumulative dose (J/cm
2): (n=85) (n=68) —
At 23 irradiations 21.2 26.9 −5.7 (−10.3 to −1.1)
(n=91) (n=93)
At end of therapy 51.5 46.1 5.4 (−5.2 to 16.0)
Proportion of side effects per
irradiation (%):
(n=93) (n=92) —
Severe erythema 5.5 3.6 1.9 (−1.1 to 4.9)
Blistering 0.3 0.6 −0.3 (−0.9 to 0.3)
Burning sensation 7.1 10.0 −2.9 (−7.1 to 1.2)
Mild erythema 28.8 28.6 0.3 (−7.4 to 8.0)
Use of adjuvant drugs‡ ‡
During waiting time§:( n =94) (n=95) —
Topical steroids 25.5 (24) 6.3 (6) 19.2 (8.8 to 29.6)
Vitamin D derivatives 18.1 (17) 6.3 (6) 11.8 (2.5 to 21.1)
During phototherapy: (n=92) (n=92)
Topical steroids 31.5 (29) 52.2 (48) −20.7 (−35.0 to −6.4)
Vitamin D derivatives 19.6 (18) 40.2 (37) −20.6 (−33.8 to −7.4)
Waiting time§ § and duration of therapy
(n=93) (n=95) —
Mean waiting time§ (weeks) 5.8 2.2 3.6 (2.9 to 4.4)
Meandurationoftherapy(weeks) 11.4 14.1 −2.7 (−4.1 to −1.2)
Mean time from inclusion to end
of therapy (weeks)
17.2 16.2 1.0 (−0.6 to 2.5)
SAPASI=self administered psoriasis area and severity index; PASI=psoriasis area and severity index. When
treatments exceeded 46 irradiations, 46 irradiations is defined as end of therapy. Values shown are calculated
from data not exceeding 46 irradiations.
*Proportion of patients achieving at least a 50%, 75%, or 90% decline of baseline SAPASI at end of therapy.
†Proportion of patients achieving at least a 50%, 75%, or 90% decline of baseline PASI at end of therapy.
‡Proportion of patients using adjuvant drugs during two consecutive phases of trial.
§Time between inclusion in trial and starting phototherapy.
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ultraviolet B treatment) a higher proportion of the
patients treated at home used these two types of drugs
(table2).Forpatientsusingadjuvantdrugs,theamount
of drug used per patientwas similar for bothtreatment
groups. During waiting time and therapy, use of other
topical and systemic drugs was negligible and did not
differ across treatment groups.
Waitingtimewaslongerforpatientstreatedathome
than for patients treated in the outpatient department
(fig 3 and table 2). This did not result in a clinically
relevant difference in total duration until the end of
treatment.
Burden of treatment
Theburdenoftreatmentwasmeasuredafter23irradia-
tions and at the end of therapy. Results for both time
points were virtually identical; therefore the overall
averagevaluesarepresented.Theburdenoftreatment
was significantly higher for patients treated in the out-
patient department than for those treated at home.
Differences in mean scores for the four domains were
1.23 to 3.01 (P≤0.001 for all; fig 4).
Quality of life
Both disease specific quality of life (psoriasis disability
index)andgenericqualityoflife(SF-36)improveddur-
ing therapy. The psoriasis disability index values
decreased from 32.8 in the home ultraviolet B group
(n=98) and 34.3 in the outpatient ultraviolet B group
(n=98)atinclusionto20.9and22.0(n=93,andn=91)at
the endoftherapy.Atallthreetimepointsofmeasure-
ment, psoriasis disability index values were similar
acrossgroups(P>0.45).TheeightSF-36domainscores
andthetwocomponentscoreswerealsosimilaracross
the groups. The values were, however, lower than the
values observed in an unaffected population sample.
39
Patients’ satisfaction and preferences
Patients treated at home evaluated their therapy more
positively than patients treated in the outpatient
department (P=0.001). For example, treatment was
rated as “excellent” by 42% (38/90) of the patients in
the home ultraviolet B group comparedwith 23% (20/
88) in the outpatient ultraviolet B group (fig 5).
Patients’ satisfaction was categorised as satisfaction
with the final treatmentresult (appearance ofskin), the
rateofimprovement,andnursingcareandsupervision
duringtreatment.Table3showsthedistributionofthe
various degrees of satisfaction for the three dimen-
sions.
Waiting time before phototherapy could be started
wassometimesconsiderable.However,26%(22/86)of
thepatientstreatedathomeand45%(26/58)treatedin
the outpatient department thought the waiting time
was not a problem, and 48% (41/86) compared with
35% (20/58) thought the waiting time was acceptable.
Onlyaminoritythoughtitwastoolong(17%v16%)or
far too long (9% v 5%; P=0.038). Despite the waiting
times, most of the participants in both groups said
that they would prefer home ultraviolet B photother-
apy in the future: 92% (83/90) of patients treated at
home compared with 60% (53/88) treated in the out-
patient department (difference 32%, 95% confidence
interval 19.5% to 44.5%). Most of the patients in both
groupsconsideredthetherapytheyreceivedtobevery
Patients recruited by participating hospitals (n=252)
Randomised (n=196)
Randomised to receive home
ultraviolet B phototherapy (n=98)
Randomised to receive conventional
outpatient ultraviolet B phototherapy (n=98)
Discontinued intervention (n=5):
  Switched to outpatient ultraviolet B
    phototherapy (n=1)
  Did not start ultraviolet B phototherapy (n=4) 
    (lesions improved in three patients during 
    waiting time, one did not want treatment
    during pregnancy)
Discontinued intervention (n=7):
  Switched to home ultraviolet B phototherapy
    (n=4)
  Did not start ultraviolet B phototherapy (n=3) 
    (lesions improved in one patient during 
    waiting time, one had agoraphobia, one
    refused to participate in trial)
Excluded (n=56):
  Did not meet inclusion criteria (n=33)
  Met exclusion criteria (n=8)
  Had already started ultraviolet B
    phototherapy (n=2)
  Excluded for other practical reasons (n=2)
  Refused to participate in trial (n=11)
Completed study (n=91) Completed study (n=87)
Included in analysis (n=98) Included in analysis (n=98)
Lost to follow-up (n=7):
  (lack of motivation to complete questionnaires
  or to visit research nurse, three were patients
  who did not start ultraviolet B phototherapy)
Lost to follow-up (n=11):
  (lack of motivation to complete questionnaires
  or to visit research nurse, two were patients
  who did not start ultraviolet B phototherapy)
Fig 2 | Flow of patients through trial
Mean time from inclusion (weeks)
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Fig 3 | Median self administered psoriasis area and severity
index (SAPASI) scores against time. 0=baseline (98 home
patients v 98 outpatients); 1=start of therapy (93 v 94), 2=23
irradiations (90 v 74), 3=end of therapy (when ultraviolet B
treatment exceeded 46 irradiations, the 46th irradiation was
defined as end of therapy; 94 v 91), 4=2 months after therapy
(51 v 43), 5=4 months after therapy (52 v 44), 6=6m o n t h s
after therapy (50 v 44), 7=8 months after therapy (50 v 43), 8=
10 months after therapy (49 v 42), 9=12 months after therapy
(47 v 40). From measurement 0-3 all 196 participants were
followed. From measurement 4-9 only a consecutive sample
of 105 participants was followed
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ultraviolet B group) or safe (52% v 63%). About 16%
(29/178)reportedbeingimpartial,andnoneofthepar-
ticipants thought the therapy they received was unsafe
(P=0.156).
DISCUSSION
In contrast to prevailing opinion,
12-25 ultraviolet B
phototherapy used at home is equally effective for
treating psoriasis as ultraviolet B phototherapy admi-
nistered in an outpatient setting and implies no addi-
tional safety hazards if applied in a setting precluding
possible non-prescribed irradiations. Furthermore,
ultraviolet B phototherapy at home poses a lower bur-
den, is better appreciated, and gives similar improve-
ments in quality of life. Most of the patients said that
they would prefer home ultraviolet B phototherapy
over therapy in an outpatient setting for future treat-
ment.
Four of six measures of the SAPASI 50, 75, and 90
and PASI 50, 75, and 90 indicated that home ultravio-
letBphototherapyforpsoriasisisatleastequallyeffec-
tive as, or even superior to, ultraviolet B phototherapy
in an outpatient department. The remaining two mea-
sures had point estimates suggesting equal effective-
ness, but from the 95% confidence intervals possible
inferiority of home ultraviolet B phototherapy could
not be entirely excluded. Also, the similar decrease in
thePASIaswellasSAPASIscoresandthevisualsever-
ity assessment score adds to the conclusion of similar
effectiveness. The proportion of patients reaching the
SAPASI 90 shows that home ultraviolet B photother-
apy may be more effective than such treatment in the
outpatient department. This was not, however, con-
firmed by the PASI 90 score. Possibly the patients’
responses may have been biased, resulting in optimis-
tic assessment on near complete recovery.
Interestingly,inbothgroupstheseverityofthepsor-
iasis had already improved during the waiting period,
before ultraviolet B phototherapy was started. This
early improvement might result from patients being
empoweredandincreasingtheircompliancewithtopi-
caldrugsaftertherecentvisittothedermatologist.The
knowledgethatultravioletBphototherapywouldsoon
be started might also have reduced possible stress fac-
torsinfluencingtheseverityofpsoriasisanditspercep-
tion. Finally, the improvement may also be partly
explained by regression to the mean.
42
Besides being equally effective, both treatments
were equally safe, as judged by the similar proportion
of acute side effects experienced and the safety of the
treatment as perceived by the patients. Therefore our
results refute the widespread fear of more acute safety
risks with ultraviolet B phototherapy used at
home.
12151619-2125
The same conclusion can be drawn about the fear of
higher cumulative doses and long term safety such as
carcinogenicity and photoageing. In our trial the final
cumulative dose of ultraviolet B light was not signifi-
cantly different between the treatment groups. As the
attributive long term risk for skin cancer caused by
ultraviolet B phototherapy is believed to correlate
directly with the experience of acute side effects and
with the total cumulative dose of ultraviolet B
light,
43-45weconcludethattheriskoffutureskincancer
attributable to treatment would also be similar across
the groups. Another argument is that a possible differ-
ence of 5.4 J/cm
2 in total cumulative dose (95% confi-
denceinterval−5.2to16.0)correspondstoadifference
Aspects of treatment
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Fig 4 | Mean burden of treatment values on a 0-10 visual
analogue scale for 92 patients randomised to receive
ultraviolet B phototherapy at home and 89 to receive
ultraviolet B phototherapy in an outpatient setting. Error bars
are 95% confidence intervals. *For example, location of
treatment (home v hospital), positioning for irradiation,
actions for patient to perform. †Includes use of creams and
ointments or taking drugs for psoriasis (87 home patients v
83 outpatients)
Table 3 |Three dimensions to measure patients’ satisfaction* with ultraviolet B phototherapy
at home or in an outpatient setting. Values are percentages (numbers) of patients unless
stated otherwise
Dimensions and items Home phototherapy Outpatient phototherapy P value†
Final treatment result‡:( n =90) (n=88)
Very satisfied 49 (44) 32 (28)
0.08
Satisfied 32 (29) 47 (41)
Somewhat satisfied 11 (10) 18 (16)
Unsatisfied 7 (6) 3 (3)
Very unsatisfied 1 (1) 0 (0)
Rate of improvement: (n=90) (n=88)
Very satisfied 36 (32) 27 (24)
0.34
Satisfied 40 (36) 44 (39)
Somewhat satisfied 18 (16) 25 (22)
Unsatisfied 4 (4) 2 (2)
Very unsatisfied 2 (2) 1 (1)
Nursing care and supervision: (n=87) (n=85)
Very satisfied 35 (30) 51 (43)
0.02
Satisfied 49 (43) 41 (35)
Somewhat satisfied 13 (11) 7 (6)
Unsatisfied 3 (3) 1 (1)
Very unsatisfied 0 (0) 0 (0)
*Prevalence of various degrees of satisfaction (very satisfied to very unsatisfied).
†Mann-Whitney U test.
‡Appearance of psoriasis.
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interval values correspond to −9 and 26). This was cal-
culated using the action spectrum from Parrish,
46 the
TL-01 emission spectrum,
47 and an average erythemal
effective dose for skin types 2 and 3 of 35 mJ/cm
2.
4849
IntheNetherlandsthemeansolarexposureis75mini-
mal erythema doses annually for indoor workers and
170 minimal erythema doses annually for outdoor
workers.
50 Therefore a mean difference of 9 minimal
erythemadosesperyearinouropinionseemsinsignif-
icant and certainly not sufficient to favour outpatient
ultraviolet B phototherapy over home treatment.
Even the extreme of the confidence intervals (26 mini-
malerythemadoses)isinouropinionstillnotsufficient
or relevant to favour one therapy over another.
Concerns about unsupervised continuation or
restart of irradiations at home is not an issue in the
Netherlands. Home ultraviolet B phototherapy units
are rented out by home care institutions only when
prescribed by a dermatologist and are collected at the
end of treatment. Therefore in this setting multiple
annualultravioletBtreatmentsareonlypossibleifpre-
scribed.Weareawarethatthissituationmaynotapply
to other countries, such as in those where patients buy
theirownunit.Onthebasisofthistrialwecannotmake
any statements on the risk of non-prescribed irradia-
tions in such settings. Recently, however, one study
51
described another measure that also provides addi-
tionalsafetythroughpreventinglongtermuseandmis-
use.ThestudyusedhomeultravioletBlightpanelsthat
were fitted with an electronic control to allow a preset
number of irradiations. When this number had been
used the patients had to contact their dermatologist
for a new code to obtain additional irradiations.
51
Other ways to prevent non-prescribed use of home
ultraviolet B light therefore exist and are being used.
Because ofthe pragmatic designofour studythe use
of concomitant drugs was permitted throughout the
trial. We observed a higher proportion of the patients
treated at home using topical steroids or vitamin D
derivatives while awaiting phototherapy. We think
this difference is attributable to the long waiting time
for home ultraviolet phototherapy, which was almost
three times as long as the average wait for treatment in
the outpatient clinic. That during ultraviolet B treat-
mentahigherproportionofpatientstreatedinhospital
used these two types of drugs might be explained by
closer supervision and more nursing care, resulting in
more motivation to use adjuvant drugs. Differential
useofdrugsduringwaitingtimeandduringultraviolet
therapy, however, had no effect on overall outcome.
The considerable waiting time before home treat-
ment resulted from the national health insurance sys-
tem and capacity problems at the home care
institutions during winter. Duration of home ultravio-
let B phototherapy was, however, shorter than outpa-
tient treatment, supposedly due to the difference in
irradiation frequency and the resulting difference in
rateofimprovement.
5253Thus,despitethelongerwait-
ing time for home ultraviolet B treatment, the mean
time from inclusion up to the end of the treatment
(waiting time plus treatment duration) was similar for
both groups.
Our findings indicate that ultraviolet B photother-
apy at home results in a lower burden of treatment
than ultraviolet B phototherapy in the outpatient
department. The results of the burden of treatment
questionnaire showed more comfort and a lower bur-
denforpatientstreatedathome.Improvementinqual-
ity of life, however, was similar for both groups. This
was because the quality of life questionnaires were not
therapy specific, but disease specific (psoriasis disabil-
ity index) or even generic (SF-36). Disease severity
decreased similarly in both groups, hence it might be
expected that general or disease specific quality of life
wouldimprovesimilarlyinthegroups.Anofficialther-
apy specific quality of life questionnaire does not exist
however. We believe that the questionnaire we devel-
oped was suitable to report burden of treatment and
can be considered a good predictor of therapy specific
quality of life.
Patientstreatedintheoutpatientsettingwereingen-
eral slightly more satisfied with the nursing care and
supervision. However, the longer waiting time for
home ultraviolet B treatment was not an issue for
most patients. In fact most participants in both groups
would prefer home ultraviolet B treatment over hospi-
tal based ultraviolet B treatment in the future. This
finding was more explicit for patients treated at home
(92%) than for those treated in outpatient departments
(60%). This difference probably results from a differ-
ence in experience with home ultraviolet B treatment,
as this item was recorded after the treatment had fin-
ished. In our opinion most patients found home ultra-
violet B phototherapy comfortable, flexible, and less
time consuming than hospital based treatment. This
led to higher reported satisfaction with home photo-
therapy than with outpatient phototherapy. Patients
therefore apparently prefer a comfortable treatment
regimen over a rapid start of treatment. This would
alsoexplainwhyhomeultravioletBtreatmentwasbet-
ter appreciated by the patients.
Patients’ evaluation
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Fig 5 | Patients’ self rated global experience of ultraviolet B
phototherapy
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As our study is the first randomised controlled trial of
ultravioletBphototherapyathome,wehavelittlewith
which to compare our results. We found only two
observational parallel group studies.
111925 In both,
home ultraviolet B phototherapy seemed to be effec-
tive.Noinformationaboutseverityofpsoriasisatbase-
line was provided, however, and neither study had a
randomised design.
1119 Patients in our trial had, as
judged by the baseline PASI and SAPASI scores, a
severity of disease ranging from mild to severe. The
average severity of psoriasis was comparable to that
of a non-selected group of 23 patients receiving ultra-
violet B phototherapy in our hospital from August
2006 to July 2007 (median SAPASI 7.55). The mean
baselinePASIandSAPASIscoresinourtrialwerealso
similartothoseofatrialwhereparticipantsweresaidto
be representative of patients receiving ultraviolet B
phototherapy
54 but were somewhat higher than those
in a study where the same principal inclusion criterion
of clinical eligibility had been used.
55
Effectiveness in terms of percentage decline in base-
linePASIandSAPASIscorewassimilartothatofthree
other trials studying the effect of narrowband ultravio-
let B light.
56-58 Effectiveness was also comparable to
thatofciclosporinandetanerceptbutsomewhathigher
than that of methotrexate and efalizumab and lower
than that of infliximab and adalimumab.
59-65 Overall
we think our results may be considered representative
and can be extrapolated to many other settings.
When it comes to safety of home ultraviolet B treat-
ment,fourofsixpublishedguidelinesonhomeultravio-
let B phototherapy for psoriasis presume that such
treatment leads to inaccurate dosimetry, suboptimal
treatment, phototoxicity, and higher attendant
risks.
1620-2225 Also, three guidelines claim that medical
supervision is crucial for treatment effect.
16202225.
Accordingly,mostpapersandguidelinesonhomeultra-
violet B phototherapy suggest caution when prescribing
thistreatmentandadviseusingstricteligibilitycriteriato
selectpatients.
8111215161820222566Inourstudyweshowed
that home ultraviolet B treatment was equally effective
and equally safe as ultraviolet B treatment in the outpa-
tient department, and that eligibility criteria for home
ultraviolet B phototherapy can be broad. To provide
an effective and safe treatment at home, we believe that
there is no need to select patients based on their pre-
sumed higher intelligence, competence, responsibility,
reliability, or compliance.
111215161820222566
Strengths and weaknesses of the study
A major strength of this study is that it is the first ran-
domised trial on the effectiveness, quality of life, and
burden of treatment of home ultraviolet B photother-
apy for psoriasis compared with standard ultraviolet B
phototherapy in an outpatient setting.
25 These issues
haveneverbeforebeenproperlyinvestigatednorpub-
lished.
We used a pragmatic design to be able to compare
the two treatments under conditions in which they
wouldbeappliedindailypractice.Thedesignensured
broadinclusionofpatientswhowereclinicallyeligible
for ultraviolet B phototherapy. We believe that our
participants adequately represent patients with psoria-
sis receiving ultraviolet B phototherapy outside the
trial. Additionally, that treatments were similar to
daily practice ensured that our results may be general-
ised to the target population. However, we recognise
that in a setting lacking control and good maintenance
of the home ultraviolet B light units, the results of the
treatment might be different.
A potential weakness may be the manner in which
data collection was planned. This was organised such
thatbothtreatmentgroupscouldbecomparedwithout
important differences in the number of irradiations.
However, this aspect of the design made it impossible
to compare the groups at fixed times—for example, at
fouroreightweeksafterthestartoftreatment.Another
point of consideration might be that during the trial
252 patients were referred to us, of whom 196 con-
sented to participate in the trial. We know why the 56
(252−196) patients were excluded.
26 It was not possi-
ble,however,tokeeparecordofallpatientswithpsor-
iasis who were prescribed narrowband ultraviolet B
phototherapy but were not referred to us for inclusion
in the trial. We therefore do not know the reasons for
non-referralandcannotentirelyexcludeselectionbias.
Such bias would, however,be minimal as the included
patients matched a consecutive sample of patients
offered ultraviolet B phototherapy in our hospital at a
later period.
Implications for practice
Our study provides proper evidence for dermatolo-
gists and dermatological societies, allowing definitive
statements about effectiveness, safety, quality of life,
and burden of treatment of ultraviolet B phototherapy
at home. Since the effectiveness of home and hospital
treatmentswasequal,futuredecisionsshouldbebased
ontheburdenoftreatment,patientsatisfaction,andthe
economic burden for society. Now that we have pro-
vided the evidence and discussed the merits of home
ultravioletBtreatment,wethinkthataconsideredpol-
icy decision and subsequent adaptation of guidelines
would be possible.
Conclusions
We have shown that ultraviolet B phototherapy at
homeisequallyeffectiveandequallysafeasultraviolet
B phototherapy in an outpatient department when
applied in a setting that precludes non-prescribed irra-
diations.Treatmentathomealsoledtoalowerburden
of treatment and greater patients’ satisfaction than did
ultraviolet B phototherapy in an outpatient setting,
despite waiting times sometimes being considerably
longer.WethereforeregardhomeultravioletBphoto-
therapy to be a worthy alternative to standard outpati-
ent ultraviolet B phototherapy for patients with
psoriasis. An economic evaluation comparing both
treatments should follow to determine which treat-
ment is economically preferred.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Two observational studies indicated that ultraviolet B phototherapy at home might be
equally effective as ultraviolet B phototherapy in an outpatient setting
Randomised evidence and evidence based guidelines on home ultraviolet B phototherapy
are lacking, and general consensus suggests being prudent
Half of dermatologists think home ultraviolet B phototherapy is inferior to outpatient
treatment, and almost a third think it carries higher risks
WHAT THIS STUDY ADDS
Randomised evidence shows that ultraviolet B phototherapy at home is at least equally
effective as and equally safe as treatment in an outpatient setting
Home treatment was associated with a lower burden of treatment and greater patients’
satisfaction
Home ultraviolet B phototherapy provides a good alternative to outpatient ultraviolet B
treatment
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